Decision Diagnostics Announces New GenAccord!(TM), Diabetic Test Strip with First Use of Its GenPrecis!(TM) Full Spread Electrode Technology
LOS ANGELES, CA / ACCESSWIRE / December 14, 2017 / Decision Diagnostics Corp. (OTC PINK: DECN) is a manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate!™ ("Sunshine") diabetes test strip, the new internationally launched GenSure!™ ("Feather") diabetes test strip, and the clinical trial ready GenChoice!™ ("Ladybug") diabetes test strip.
Additionally, DECN is in the final stages of preparation for the international pre-market launch and the filing of a 510K application with the U.S. FDA for its GenChoice!™ ("Ladybug") diabetes test strips, and the company's GenPrecis!™ ("Dragonfly") Precise glucometer and diabetes test strip, a product in advanced development and designed for use by children and for general commercial sale.
Today, we are pleased to announce that the 2018 marketplace that will greet GenAccord!™ ("Bumble Bee") our newest product concept now in research and development. GenAccord!™ is the first direct outgrowth of our GenPrecis!™ full spread electro-chemistry technology. Our new test strip can work equally well either on newer technology meters or on vintage electro-chemistry meters. Our first implementation of GenAccord!™ will be a legacy family of meters with 800,000 total users (Generation 1 and Generation 2) in use worldwide. Future implementations could include several families of legacy meters manufactured by different legacy manufacturers."
We ask that all interested parties watch for our discussion.
